JP7355382B2 - Ａｒｃカプシドの組成物及び使用方法 - Google Patents

Ａｒｃカプシドの組成物及び使用方法 Download PDF

Info

Publication number
JP7355382B2
JP7355382B2 JP2019561875A JP2019561875A JP7355382B2 JP 7355382 B2 JP7355382 B2 JP 7355382B2 JP 2019561875 A JP2019561875 A JP 2019561875A JP 2019561875 A JP2019561875 A JP 2019561875A JP 7355382 B2 JP7355382 B2 JP 7355382B2
Authority
JP
Japan
Prior art keywords
arc
protein
mrna
capsid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019561875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523983A (ja
JP2020523983A5 (https=
Inventor
ジェイソン ディー シェパード
キャメロン デイ
エリッサ パストゥジン
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2020523983A publication Critical patent/JP2020523983A/ja
Publication of JP2020523983A5 publication Critical patent/JP2020523983A5/ja
Priority to JP2023076834A priority Critical patent/JP7774319B2/ja
Application granted granted Critical
Publication of JP7355382B2 publication Critical patent/JP7355382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019561875A 2017-05-10 2018-05-10 Ａｒｃカプシドの組成物及び使用方法 Active JP7355382B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076834A JP7774319B2 (ja) 2017-05-10 2023-05-08 Ａｒｃカプシドの組成物及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762504370P 2017-05-10 2017-05-10
US62/504,370 2017-05-10
US201762543130P 2017-08-09 2017-08-09
US62/543,130 2017-08-09
PCT/US2018/032105 WO2018209113A1 (en) 2017-05-10 2018-05-10 Compositions and methods of use of arc capsids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076834A Division JP7774319B2 (ja) 2017-05-10 2023-05-08 Ａｒｃカプシドの組成物及び使用方法

Publications (3)

Publication Number Publication Date
JP2020523983A JP2020523983A (ja) 2020-08-13
JP2020523983A5 JP2020523983A5 (https=) 2021-07-26
JP7355382B2 true JP7355382B2 (ja) 2023-10-03

Family

ID=64104936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019561875A Active JP7355382B2 (ja) 2017-05-10 2018-05-10 Ａｒｃカプシドの組成物及び使用方法
JP2023076834A Active JP7774319B2 (ja) 2017-05-10 2023-05-08 Ａｒｃカプシドの組成物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076834A Active JP7774319B2 (ja) 2017-05-10 2023-05-08 Ａｒｃカプシドの組成物及び使用方法

Country Status (7)

Country Link
US (1) US20210189432A1 (https=)
EP (1) EP3621660A4 (https=)
JP (2) JP7355382B2 (https=)
CN (1) CN110997011A (https=)
AU (1) AU2018265395B2 (https=)
CA (1) CA3062614A1 (https=)
WO (1) WO2018209113A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20210163933A1 (en) * 2017-12-11 2021-06-03 University Of Massachusetts Arc protein extracellular vesicle nucleic acid delivery platform
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
EP4334445A4 (en) * 2021-05-04 2025-09-03 Univ Cornell MODIFIED EXTRACELLULAR VESICLES
EP4565594A2 (en) * 2022-08-01 2025-06-11 University of Utah Research Foundation Compositions and methods for labeling and detecting binding partners
CN118576725B (zh) * 2024-08-02 2025-06-03 中国人民解放军军事科学院军事医学研究院 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用
CN120248078B (zh) * 2025-05-28 2025-11-28 中国人民解放军军事科学院军事医学研究院 一种基于arc蛋白的修饰多肽及其作为核酸递送载体的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042727A1 (en) 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
JP2016526045A (ja) 2013-05-31 2016-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルス変異体及びその使用方法
US20170087087A1 (en) 2015-09-28 2017-03-30 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US7638269B2 (en) * 1997-02-07 2009-12-29 The Regents Of The University Of California Viral capsid assembly intermediates and methods of production
CA2714972A1 (en) * 2008-02-08 2009-08-13 University Health Network Use of p27kip1 for the prevention and treatment of heart failure
EP2391638B1 (en) * 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2012062873A2 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042727A1 (en) 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
JP2016526045A (ja) 2013-05-31 2016-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルス変異体及びその使用方法
US20170087087A1 (en) 2015-09-28 2017-03-30 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochem. J.，2015年，Vol. 468，pp. 145-158
Biochem. J.，2015年，Vol. 469，pp. e1-e3
Neuron，2013年，Vol. 78，pp. 1024-1035
Neuron，2015年，Vol. 86, Issue 2，pp. 490-500

Also Published As

Publication number Publication date
JP2020523983A (ja) 2020-08-13
US20210189432A1 (en) 2021-06-24
JP2023106451A (ja) 2023-08-01
CA3062614A1 (en) 2018-11-15
EP3621660A4 (en) 2021-01-20
AU2018265395A1 (en) 2019-12-05
JP7774319B2 (ja) 2025-11-21
WO2018209113A1 (en) 2018-11-15
AU2018265395B2 (en) 2025-04-10
CN110997011A (zh) 2020-04-10
EP3621660A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
JP7355382B2 (ja) Ａｒｃカプシドの組成物及び使用方法
Pastuzyn et al. The neuronal gene arc encodes a repurposed retrotransposon gag protein that mediates intercellular RNA transfer
US10538570B2 (en) Targeted and modular exosome loading system
US20210163933A1 (en) Arc protein extracellular vesicle nucleic acid delivery platform
Zhu et al. VCP suppresses proteopathic seeding in neurons
US20250163126A1 (en) Artificial synapses
JP2011523353A (ja) 細胞透過のための過剰に荷電されたタンパク質
JP2024541545A (ja) 工学的マイグラソームおよびその作製方法およびその使用
US7132399B2 (en) Mammalian cell surface DNA receptor
JP6618079B2 (ja) エクソソーム産生促進剤
US7390625B2 (en) Apoptosis-associated protein and use thereof
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
US7700361B2 (en) Secretory or membrane protein expressed in skeletal muscles
EP1433849A1 (en) NOVEL POLYPEPTIDE, DNA THEREOF AND USE OF THE SAME
US20090170773A1 (en) Novel use of g-protein-conjugated receptor and ligand thereof
US10822401B2 (en) MZB1, a novel B cell factor, and uses thereof
CN102355911A (zh) 调节脂肪生成的Vgll3活性调节剂的用途
KR20160001917A (ko) 뇌 특이적 핵산 전달
HK40100341A (zh) 靶向pacs1的化合物及其使用方法
Drasbek Molecular Characterization of Native and Recombinant Ionotrophic Glutamate Receptors Expressed in Neurons and Heterologous Systems
Cik Molecular characterisation of the N-methyl-D-aspartate receptor expressed in mammalian cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230104

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230913

R150 Certificate of patent or registration of utility model

Ref document number: 7355382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150